U.S. Airlines Stock News

FitLife Brands shares slipped about 3.5% to US$10.80 after Q2 numbers hit the tape, which suggests sentiment moved faster than the headline figures. The stock entered the release with a slightly positive three-month return, so today’s drop stands out. The core story is not a collapse in earnings. Revenue reached US$26.5m and net income came in at US$2.0m, supported by the Irwin acquisition. The main point of concern is sentiment around margins, with gross margin at 37.0% as investors weigh...

Earlier this week, Rezolve AI launched Rezolve Provenance, a patent-backed, model-agnostic platform that marks, signs and verifies AI-generated or modified content across enterprise and commerce workflows, including C2PA Content Credentials, embedded image watermarking, secure provenance records and verification APIs. An interesting angle is that Rezolve Provenance directly targets new EU AI Act transparency rules on machine-readable marking of AI content, positioning the platform as...

Amaroq stock barely flinched after its Q2 release, slipping just 0.4% today, even though the report marked a clear sentiment break from the company’s loss making past. The market kept its cool while Amaroq posted Q2 revenue of C$37.3m and net income of C$11.1m, turning what had been a story of build out into one of cash generation. The real headline is the earnings swing. Trailing twelve month Basic EPS has moved into positive territory, backed by first half gross profit of C$34.9m. Price...

CorMedix went into this print with a value story and a low P/E multiple that had already caught investor attention. The stock still dropped 7.4% to close near US$7.54 after the report. This suggests that emotion is running ahead of the headline numbers. The quarter itself was not a collapse story. CorMedix posted Q2 revenue of US$101.9m and net income of US$25.8m, and management raised full year adjusted EBITDA guidance to a range of US$125m to US$140m. That creates a clear expectation gap...

Ondas stock closed Friday at US$9.24, up 3.7%, as investors reacted to a headline quarter that mixed eye catching revenue with a sharp swing back into losses. Q2 revenue landed at about US$83.8m, which is a huge step up for a defense and autonomy platform of this size. However, the company reported a net loss of roughly US$88.6m and a basic loss per share of US$0.18. Short term traders are cheering the top line. Long term investors will be more focused on what this says about Ondas' margin...

Zacks recently rated Pebblebrook Hotel Trust as a Rank #1 (Strong Buy) with a top Value Score, highlighting it as potentially undervalued versus its REIT peers based on earnings outlook and valuation metrics. This recognition has drawn fresh attention to Pebblebrook’s fundamentals, suggesting that its earnings profile and balance sheet strength may be gaining broader investor appreciation. Building on Zacks’ Strong Buy and value designation, we’ll now examine how this endorsement interacts...

Nu Holdings recently reported record second-quarter 2026 net income of about US$1.10 billion, a roughly half increase year over year, alongside strong customer growth to 139 million, expanding credit volumes, and new full banking licenses in Brazil and Mexico. An interesting angle is the newly authorized US$1.00 billion share buyback and Nu’s heavier use of AI, now handling most customer-support interactions in Brazil while informing credit and growth decisions across its Latin American...

SKYX Platforms stock inched up about 2% to US$1.12 today, a modest rebound after a weaker month, while the latest earnings laid out a more complicated picture. Revenue reached US$25.3 million for the quarter and losses remained significant, with net income still firmly in the red. The real story for you is not today’s small price move; it is the tension between a growing top line and an ongoing loss profile that still needs to be closed over the coming years. Is SKYX Platforms trading at a...

Lemonade stock has delivered a very strong 3 year return, yet the current checks still flag it as expensive rather than a clear bargain. Recent news around record revenue and AI driven expansion keeps expectations high, while the broader valuation profile looks more demanding. Over the past 3 years, Lemonade has returned about 276.3%, which sets a high bar for future gains to justify the current price. The push to widen its insurance footprint and use AI in underwriting and claims can...

EagleRock Land slipped 0.8% to close at US$25.02 today, a modest pullback for a stock that is still up over the past month. The headline from this earnings release is not the share price; it is the margin story behind a young, land focused energy infrastructure platform that is generating high free cash flow from a lean cost base. Q2 revenue reached US$41.5 million and free cash flow conversion ran high, backed by a roughly three quarters EBITDA margin on a normalized basis. For investors,...

Blaize Holdings came into this earnings print with a bruised stock and a big growth story attached to artificial intelligence chips. That story met a harsh reset. The stock collapsed about 49% today to roughly $0.59 after management slashed 2026 revenue guidance to a range of $40 million to $43 million from about $130 million. For a company often framed as a high growth revenue play, the headline is now the depth of that guidance cut rather than the sharp jump in recent quarterly sales. The...

Recently, Apple confirmed it is working with Alibaba to integrate Alibaba’s Qwen AI model into Apple Intelligence for devices sold in China, subject to Chinese regulatory approval and aligned with Apple’s newly trained, China-specific large language model. This collaboration highlights Alibaba’s role as a key AI infrastructure partner for global technology companies operating under China’s tightening tech rules, particularly through its Qwen model and licensing approach. Next, we will...

Lifeway Foods stock jumped 4.5% to US$25.82 after the Q2 print, even though the headline earnings per share slipped to roughly one cent on net income of about US$0.1m. The market cheered at first, then the details started to sink in. The real story is the squeeze in profitability for this growing dairy and probiotics producer. Trailing net profit margin now sits at 4.5%, lower than a year ago, even as revenue has scaled higher over recent quarters. The rest of this earnings breakdown examines...

In August 2026, Charles River Laboratories International reported second-quarter results showing revenue of US$1,004.08 million and a small net loss of US$1.48 million, while also lowering its 2026 GAAP EPS guidance to US$3.05–US$3.35 per share and projecting a 2.5%–3.5% revenue decline due mainly to divestiture-related losses. Despite the weaker GAAP outlook, management highlighted a return to organic revenue growth and improving demand in its Discovery and Safety Assessment segment,...

SBC Medical Group Holdings just jumped 14.7% in a single session, yet the real story sits in the operating engine the market is trying to price. You are looking at a healthcare stock that came into today trading on a trailing P/E of 7.7x while reporting a trailing net profit margin of 28%. Those are punchy numbers for a clinic roll up model and they sit alongside a full year earnings growth figure of 47.1%. Today’s earnings are the latest test of whether that gap between price and reported...

CapsoVision entered this earnings day with its stock roughly flat over three months, then slipped 4.9% to close at US$6.46. That pullback sits awkwardly against a company still priced at a rich 23.8x P/S, compared with far lower multiples across the medical equipment peer group. The headline from this print is not the top line. It is the pressure that elevated valuation now carries on an unprofitable business, even as trailing 12 month revenue reached about US$13.6m. The gap between price and...

ADI Global Distribution walked into this earnings season with a premium P/E tag and a fresh turn into profitability. The stock just dropped 17.7% in a single session. That move jars with a quarter that shows revenue of US$1,286 million and a return to a modest profit of US$6 million, especially against the heavy losses investors saw a year ago. The real story here is not spectacular growth; it is the fragile but real shift from red ink to black ink, and the market’s sudden decision to punish...

In August 2026, Ingredion Incorporated reported second-quarter 2026 results showing sales of US$1,850 million, lower earnings per share versus the prior year, confirmed it had completed a US$77.82 million buyback of 673,000 shares under its existing program, and reaffirmed full-year 2026 EPS guidance of US$9.15 to US$9.75 despite expecting a low double-digit drop in reported operating income. The company expects full-year 2026 net sales to be flat to up low single digits, reflecting volume...

Abeona Therapeutics stock slipped about 6% today, yet the earnings story is less about a miss and more about a reality check on what early commercial gene therapy looks like. Investors came in after a weak month for the stock and met a report that paired rising ZEVASKYN revenue of US$11.38m in the quarter with a heavy quarterly net loss of US$20.19m. The market appears to be reacting more to the size of the loss than to the evidence that paying patients are now flowing through the system. The...

Fate Therapeutics stock edged up about 2% today, a muted reaction for a biotech still burning cash while trying to prove its science. The headline is not the share move. It is another quarter of meaningful losses, with Q2 net loss sitting around US$30 million and basic loss per share close to US$0.25. Revenue remains in the low single digit millions. The market seems to be treating this as business as usual for a high risk pipeline story rather than a turning point on the income statement. Is...

StoneCo walked into this earnings print as a heavily discounted fintech stock, trading on a P/E of 3.2x and already down double digits over the past month. The market still hit it again, with the share price falling 6.6% today. That reaction sits awkwardly next to trailing net profit margin of 26.8% and earnings that rose strongly over the last year. The real headline is not revenue volume or client count. It is the tug of war between those fat margins and the pressure from weak interest...

In August 2026, Babcock & Wilcox Enterprises, Inc. reported second-quarter sales of US$319.72 million and net income of US$14.26 million, alongside a separate agreement with Siemens Energy AG to commence work on 20 steam turbine generator sets totaling 1 GW for its FastPower program serving data center projects. Together, the return to profitability and the Siemens Energy turbine agreement highlight Babcock & Wilcox’s push to supply fast-to-deploy power solutions for energy-hungry data...

Telesat stock slipped 3.8% to $50.64 today, yet the real story sits on the income statement. The satellite operator posted Q2 revenue of $79.5m and a net loss of $559m, with the loss heavily shaped by a large non cash hit linked to Lightspeed warrants and foreign exchange on United States dollar debt. For a company often framed as a high growth, low Earth orbit opportunity, this quarter put the focus squarely on how much profit pressure the current build out is placing on the business. Love...

Eton Pharmaceuticals just delivered the kind of quarter that sends sentiment into overdrive. The stock rose 44.3% to US$58.86 in regular trading, as investors rushed to reprice a business that has moved firmly into profit. The headline is simple: Q2 net income reached US$11.6m and basic earnings per share came in at US$0.42, backed by US$37.6m of revenue in this specialty pharma portfolio. The central question now is whether that large one day move reflects a rational reset around a new...